Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Feb 24, 2023 1:19pm
54 Views
Post# 35303816

RE:RE:RE:PLX vol. 2.5 million shares with only 50 million outstanding

RE:RE:RE:PLX vol. 2.5 million shares with only 50 million outstandingGood for Protalix, poof. Up almost double (90%). What does that have to do with Bioasis share price of 1.5¢?

Yep, PRX was over $6 when they got a Complete Response Letter (CRL) from the FDA. Usually a CRL is fatal but not really so with PRX-102. Because of Covid, and because Protalix's submission was obsolete, and the FDA couldn't complete it's work before the extension, the CRL was issued. The CRL did not directly relate to the performance of PRX-102. Approval continues to be expected for that drug.

About the PRX share price of $6 at the time, I can't explain it other than maybe the S&P Biotech ETF was up 5% just about then.

jd
<< Previous
Bullboard Posts
Next >>